Progressive multifocal leukoencephalopathy in a renal transplant patient

J Neurovirol. 2019 Aug;25(4):612-615. doi: 10.1007/s13365-019-00749-8. Epub 2019 May 8.

Abstract

End-stage renal disease (ESRD) has a major impact on health and affects more than 600,000 people in the USA. The current mainstay treatments include dialysis and kidney transplantation (KT), and patients who have received KT have a higher quality of life and a lower mortality risk than those on chronic dialysis. Therefore, KT is considered the more preferred treatment modality for patients with ESRD. However, even though KT results in a higher long-term survival rate, the use of immunosuppressants is associated with various complications, including opportunistic infections and malignancies, which may lead to a higher risk of death in the first year after transplantation. Progressive multifocal leukoencephalopathy (PML) is a rare complication following KT, with an incidence of 0.027% in KT recipients. We present a case of PML following immunosuppressant therapy in a patient who received KT.

Keywords: Immunosuppressant agents; JC virus; Kidney transplantation; Progressive multifocal leukoencephalopathy.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Humans
  • Immunocompromised Host*
  • Immunosuppressive Agents / adverse effects
  • JC Virus / genetics*
  • JC Virus / isolation & purification
  • Kidney / immunology
  • Kidney / pathology
  • Kidney / surgery
  • Kidney / virology
  • Kidney Failure, Chronic / immunology*
  • Kidney Failure, Chronic / pathology
  • Kidney Failure, Chronic / surgery
  • Kidney Failure, Chronic / virology
  • Kidney Transplantation / adverse effects*
  • Leukoencephalopathy, Progressive Multifocal / etiology
  • Leukoencephalopathy, Progressive Multifocal / immunology*
  • Leukoencephalopathy, Progressive Multifocal / surgery
  • Leukoencephalopathy, Progressive Multifocal / virology
  • Middle Aged
  • Polymerase Chain Reaction

Substances

  • Immunosuppressive Agents